WO2001046394A3 - Mammalian protein phosphatases - Google Patents

Mammalian protein phosphatases Download PDF

Info

Publication number
WO2001046394A3
WO2001046394A3 PCT/US2000/034736 US0034736W WO0146394A3 WO 2001046394 A3 WO2001046394 A3 WO 2001046394A3 US 0034736 W US0034736 W US 0034736W WO 0146394 A3 WO0146394 A3 WO 0146394A3
Authority
WO
WIPO (PCT)
Prior art keywords
phosphatase
mammalian protein
protein phosphatases
various
polypeptides
Prior art date
Application number
PCT/US2000/034736
Other languages
French (fr)
Other versions
WO2001046394A2 (en
Inventor
Gregory D Plowman
Ricardo Martinez
David Whyte
Gerard Manning
Sucha Sudarsanam
Ronald J Hill
Peter Flanagan
Original Assignee
Sugen Inc
Gregory D Plowman
Ricardo Martinez
David Whyte
Gerard Manning
Sucha Sudarsanam
Ronald J Hill
Peter Flanagan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen Inc, Gregory D Plowman, Ricardo Martinez, David Whyte, Gerard Manning, Sucha Sudarsanam, Ronald J Hill, Peter Flanagan filed Critical Sugen Inc
Priority to EP00988227A priority Critical patent/EP1299525A2/en
Priority to JP2001546892A priority patent/JP2003517836A/en
Priority to AU24456/01A priority patent/AU2445601A/en
Priority to US10/168,506 priority patent/US20040053229A1/en
Priority to CA002395093A priority patent/CA2395093A1/en
Publication of WO2001046394A2 publication Critical patent/WO2001046394A2/en
Publication of WO2001046394A3 publication Critical patent/WO2001046394A3/en
Priority to US10/838,181 priority patent/US20050084877A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

The present invention relates to phosphatase polypeptides, nucleotide sequences encoding the phosphatase polypeptides, as well as various products and methods useful for the diagnosis and treatment of various phosphatase-related diseases and conditions. Through the use of a bioinformatics strategy, mammalian members of the MAP kinase hosphatase PTP's and STP's have been identified and their protein structure predicted.
PCT/US2000/034736 1999-12-21 2000-12-21 Mammalian protein phosphatases WO2001046394A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP00988227A EP1299525A2 (en) 1999-12-21 2000-12-21 Mammalian protein phosphatases
JP2001546892A JP2003517836A (en) 1999-12-21 2000-12-21 Mammalian protein phosphatase
AU24456/01A AU2445601A (en) 1999-12-21 2000-12-21 Mammalian protein phosphatases
US10/168,506 US20040053229A1 (en) 2000-12-21 2000-12-21 Mammalian protein phosphatases
CA002395093A CA2395093A1 (en) 1999-12-21 2000-12-21 Mammalian protein phosphatases
US10/838,181 US20050084877A1 (en) 1999-12-21 2004-05-04 Mammalian protein phosphatases

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US17325599P 1999-12-21 1999-12-21
US60/173,255 1999-12-21
US17576699P 1999-12-28 1999-12-28
US60/175,766 1999-12-28
US17807800P 2000-01-25 2000-01-25
US60/178,078 2000-01-25
US17930100P 2000-01-31 2000-01-31
US60/179,301 2000-01-31

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/838,181 Division US20050084877A1 (en) 1999-12-21 2004-05-04 Mammalian protein phosphatases

Publications (2)

Publication Number Publication Date
WO2001046394A2 WO2001046394A2 (en) 2001-06-28
WO2001046394A3 true WO2001046394A3 (en) 2002-05-02

Family

ID=27497049

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/034736 WO2001046394A2 (en) 1999-12-21 2000-12-21 Mammalian protein phosphatases

Country Status (3)

Country Link
JP (1) JP2003517836A (en)
AU (1) AU2445601A (en)
WO (1) WO2001046394A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057221A2 (en) * 2000-02-02 2001-08-09 Ceptyr, Inc. Dsp-12 and dsp-13 dual-specificity phosphatases
AU2001245463A1 (en) * 2000-03-07 2001-09-17 Millennium Pharmaceuticals, Inc. 26583, a novel serine/threonine phosphatase and uses therefor
EP1268818A2 (en) * 2000-03-24 2003-01-02 Millennium Pharmaceuticals, Inc. 18221, dual specificity phosphatase and uses thereof
US7250279B2 (en) 2000-04-07 2007-07-31 Merck Patent Gmbh Human pyruvate dehydrogenese phosphatase
CA2405725A1 (en) * 2000-04-10 2001-10-18 Merck Patent Gesellschaft Mit Beschraenkter Haftung Identification of a novel dual specificity phosphataes
WO2001083723A2 (en) * 2000-05-02 2001-11-08 Ceptyr, Inc. Dsp-14 dual-specificity phosphatase
AU2002212980A1 (en) * 2000-09-25 2002-04-02 Millennium Pharmaceuticals, Inc. 69109, a novel human tyrosine phosphatase and uses therefor
WO2002026997A2 (en) * 2000-09-26 2002-04-04 Ceptyr, Inc. Dsp-16 dual-specificity phosphatase
MXPA03005436A (en) 2000-12-20 2004-05-05 Bristol Myers Squibb Co Polynucleotides encoding novel human phosphatases.
WO2002063014A2 (en) * 2001-02-05 2002-08-15 Bayer Aktiengesellschaft Human tyrosine-specific protein phosphatase
WO2003025196A2 (en) * 2001-05-16 2003-03-27 Ceptyr, Inc. Dsp-18 dual-specificity phosphatase
AU2003239897A1 (en) 2002-05-23 2003-12-12 Ceptyr, Inc. Modulation of ptp1b signal transduction by rna interference
JP2004147527A (en) * 2002-10-29 2004-05-27 Japan Science & Technology Agency Enzyme for dephosphorylating actin depolymerization factor, cofilin, and gene therefor
JP2007089524A (en) * 2005-09-29 2007-04-12 Tokyo Univ Of Agriculture & Technology SYSTEM FOR SELECTING delta-ENDOTOXIN VARIANT HAVING IMPROVED EFFECT ON TARGET INSECT
JPWO2007037555A1 (en) * 2005-09-30 2009-04-16 リンク・ジェノミクス株式会社 Therapeutic or diagnostic use of DUSP15 gene
GB201522667D0 (en) * 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997006245A1 (en) * 1995-08-04 1997-02-20 Medical Research Council Map kinase phosphatase gene and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997006245A1 (en) * 1995-08-04 1997-02-20 Medical Research Council Map kinase phosphatase gene and uses thereof

Non-Patent Citations (24)

* Cited by examiner, † Cited by third party
Title
COHEN P T W: "Novel protein serine/threonine phosphatases: variety is the spice of life", TRENDS IN BIOCHEMICAL SCIENCES, vol. 22, no. 7, 1 July 1997 (1997-07-01), pages 245 - 251, XP004081591, ISSN: 0968-0004 *
DATABASE EMBL 10 November 1993 (1993-11-10), LAWSON JE ET AL: "Bos taurus pyruvate dehydrogenase phosphatase mRNA", XP002175558 *
DATABASE EMBL 11 March 1999 (1999-03-11), STOTHARD PM & D PILGRIM: "Mus musculus clone mouse1-9 putative protein phosphatase type 2C mRNA", XP002175556 *
DATABASE EMBL 13 April 1995 (1995-04-13), MAURO LJ ET AL: "Rattus norwegicus protein tyrosine phosphatase mRNA", XP002175560 *
DATABASE EMBL 15 December 1998 (1998-12-15), MUDA M ET AL: "Dual specificity protein phosphatase 9 (Mitogen-activated protein kinase phosphtase 4)", XP002167400 *
DATABASE EMBL 15 December 1999 (1999-12-15), SMITH DR: "Homo sapiens chromosome 10 clone RP11-77G23", XP002175551 *
DATABASE EMBL 17 May 1999 (1999-05-17), MUZNY DM ET AL: "Homo sapiens chromosome 12 clone RP11-689B22", XP002167399 *
DATABASE EMBL 19 June 1998 (1998-06-19), NCI-CGAP: "ov60e06.x1 Soares_testis_NHT Homo sapiens cDNA clone", XP002175554 *
DATABASE EMBL 23 June 1996 (1996-06-23), HILLIER L ET AL: "zd58b10.r1 Soares_fetal-heart_NbHH19W Homo sapiens cDNA clone", XP002175553 *
DATABASE EMBL 24 May 1999 (1999-05-24), MUZNY DM ET AL: "Homo sapiens 12p BAC RP11-253I19", XP002175546 *
DATABASE EMBL 3 September 1998 (1998-09-03), WOESSNER J ET AL: "Homo sapiens full length insert cDNA clone YW04H08", XP002175547 *
DATABASE EMBL 4 April 1996 (1996-04-04), HILLIER L. ET AL: "zb04d10.s1 Soares_fetal_lung_NbHL19W Homo sapiens cDNA clone", XP002175549 *
DATABASE EMBL 5 May 1999 (1999-05-05), NCI-CGAP: "wa98a11.x1 NCI_CGAP_GC6 Homo sapiens cDNA clone", XP002167398 *
DATABASE EMBL 6 March 1998 (1998-03-06), DAVIES KE & A THEODOSIOU: "Sequence 6 fro Patent WO9706245" *
DATABASE EMBL 8 January 1998 (1998-01-08), HILLIER L ET AL: "zg88b02.s1 Soares_fetal-heart_NbHH19W Homo sapiens cDNA clone", XP002175552 *
DATABASE GENESEQ 29 December 1998 (1998-12-29), DAVIS AR ET AL: "Mutant osteotesticular protein tyrosine phosphatase protein", XP002175561 *
DATABASE GENSEQ 15 December 1997 (1997-12-15), DAVIES KE & A THEODOSIOU: "Dual specific murine threonine-tyrosine phosphatase M3/6" *
DATABASE SWALL 1 February 1994 (1994-02-01), YI H ET AL: "Dual specificity protein phosphatase 2", XP002175548 *
DATABASE SWALL 1 June 1994 (1994-06-01), LAWSON JE ET AL: "Pyruvate dehydrogenase phosphatase, catalytic subunit 1", XP002175559 *
DATABASE SWALL 1 May 1999 (1999-05-01), STOTHARD PM & D PILGRIM: "Hypothetical 18.9 kDa protein", XP002175557 *
DATABASE SWALL 1 November 1999 (1999-11-01), THEODOSIOU A ET AL: "Dual specificity phosphatase MKP-5", XP002175555 *
DATABASE SWALL 1 October 1996 (1996-10-01), ISHIBASHI T ET AL: "Dual specificity protein phosphatase 3", XP002175550 *
HOOFT VAN HUIJSDUIJNEN R: "Protein tyrosine phosphatases: counting the trees in the forest", GENE, vol. 225, no. 1-2, 28 December 1998 (1998-12-28), pages 1 - 8, XP004153614, ISSN: 0378-1119 *
KEYSE S M: "AN EMERGING FAMILY OF DUAL SPECIFICITY MAP KINASE PHOSPHATASES", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1265, 1995, pages 152 - 160, XP000196716, ISSN: 0167-4889 *

Also Published As

Publication number Publication date
AU2445601A (en) 2001-07-03
JP2003517836A (en) 2003-06-03
WO2001046394A2 (en) 2001-06-28

Similar Documents

Publication Publication Date Title
WO2001046394A3 (en) Mammalian protein phosphatases
WO2000073469A3 (en) Protein kinases
WO2001038503A3 (en) Novel human protein kinases and protein kinase-like enzymes
WO2005000200A3 (en) Novel kinases
WO2000031235A3 (en) Nucleotide and protein sequences of nogo genes and methods based thereon
WO2001083782A3 (en) Novel proteases
WO2004006838A3 (en) Novel kinases
WO2000053758A3 (en) Compositions and methods for the treatment of immune related diseases
CA2257133A1 (en) Human dnase i hyperactive variants
IL153442A0 (en) Treatment of central nervous system diseases by antibodies against glatiramer acetate
WO1998014596A3 (en) Disease associated protein tyrosine phosphatases
WO2005040418A3 (en) Compositions for diagnosis and therapy of diseases associated with aberrant expression of futrins (r-spondins) and/or wnt
WO2001066594A3 (en) Human protein kinases and protein kinase-like enzymes
WO2001064877A3 (en) Human schizophrenia gene
WO1999025829A3 (en) Cdk2 protein and cdk2 protein complexes
WO2002064737A3 (en) Antisense modulation of protein phosphatase 2 catalytic subunit beta expression
WO2001092491A3 (en) Mammalian protein phosphatases identified by in-silico analysis
WO1999066051A3 (en) Nek-related and bub1-related protein kinases
WO2001055356A3 (en) Human protein kinases and protein kinase-like enzymes
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases
WO2001077338A3 (en) Human protein kinases and protein kinase-like enzymes
WO2001064876A3 (en) Human schizophrenia gene
WO2001096873A3 (en) Method for identifying apoptosis-modified proteins
WO2000015797A3 (en) Compositions and methods for the treatment of immune related diseases
WO1997040134A3 (en) Human dnase ii

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2395093

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000988227

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 546892

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 10168506

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000988227

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000988227

Country of ref document: EP